| Business Summary | | Corvas
International,
Inc.
is
a
biopharmaceutical
company
engaged
in
the
discovery,
development
and
commercialization
of
novel
therapeutics
that
address
large
markets
such
as
cardiovascular
disease,
stroke
and
cancer.
The
Company
has
two
product
candidates
in
Phase
II
clinical
trials.
Its
lead
product
candidate,
partnered
with
Pfizer,
is
UK-279,276,
formerly
rNIF,
a
recombinant
protein
in
Phase
IIb
clinical
trials
for
the
treatment
of
reperfusion
injury
associated
with
ischemic
stroke.
The
Company's
second
product
candidate,
rNAPc2,
is
a
recombinant
protein
that
the
Company
is
developing
for
the
prevention
of
deep
vein
thrombosis
and
pulmonary
embolism,
and
for
the
treatment
of
unstable
angina.
The
Company
also
has
a
number
of
research
programs
aimed
at
developing
novel
drugs
to
modulate
proteases
involved
in
cancer
and
other
diseases. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Corvas
International
is
engaged
in
the
design
and
development
of
a
new
generation
of
therapeutic
agents
in
the
fields
of
blood
clot
formation
(thrombosis),
inflammation,
cancer
and
other
diseases.
For
the
six
months
ended
6/30/01,
revenues
decreased
96%
to
$163
thousand.
Net
loss
totalled
$14.1
million,
up
from
$4.5
million.
Revenues
reflect
the
contractual
end
of
the
collaborative
agreements
with
Schering-Plough.
Loss
reflects
increased
R&D
due
to
the
manufacturing
of
rNAPc2. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| M. Blake Ingle, Ph.D., 58 Chairman | -- | -- | Randall Woods, 49 Pres,
CEO, Director | $498K | $1.2M | George Vlasuk, Ph.D., 45 Exec.
VP of R&D, CSO, Director | 353K | 893K | Carolyn Felzer, 44 VP,
Controller, Assistant Sec. | 155K | 43K | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|